Advertisement

Topics

Companies Related to "Post-dilatation for Optimization of Drug-eluting Stents (DES) Deployment Assessed by Intravascular Ultrasound Multicenter Analysis" [Most Relevant Company Matches] RSS

06:28 EST 17th February 2019 | BioPortfolio

Here are the most relevant search results for "Post-dilatation for Optimization of Drug-eluting Stents (DES) Deployment Assessed by Intravascular Ultrasound Multicenter Analysis" found in our extensive corporate database of over 50,000 company records.

Showing "Post dilatation Optimization Drug eluting Stents Deployment Assessed" Companies 1–25 of 4,200+

Extremely Relevant

CorNova Inc.

CorNova is a developer of next-generation endovascular products designed to integrate new technologies into existing products and procedures, resulting in better patient outcomes without added procedure time, cost and patient risk. The company's FiberHalo(TM) stent deployment and post-dilatation angioplasty balloon catheters are designed to provide stent lumen area measurement within the angiopla...


InspireMD

InspireMD Ltd. is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD's mission is to utilize its proprietary technology to make its products the industry standard fo...

Inspire MD

InspireMD is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD's mission is to utilize its proprietary technology to make its products the industry standard for ste...


Relevant

IMBiotechnologies Ltd

IMBio is a privately held Canadian biotechnology company focused on developing medical device products for use in the area of embolotherapy. Lead product, OCL 500 microspheres for the treatment of unresectable/inoperable hypervascularized tumours has received marketing clearance from the FDA in the U.S. Other products in development include rapidly-dissolving, drug-eluting and/or radio-labelle...

Elixir Medical Corporation

Elixir Medical is developing a wide range of drug and device platforms for vascular therapies. These include drug eluting stent systems with durable and bioabsorbable polymers, and fully bioresorbable drug eluting stent systems.

AcuityBio Inc. and Cook Biotech Inc.

AcuityBio has developed a platform technology for localized, sustained, safe drug-delivery to be used in the prevention of post-surgical lung cancer recurrence. ABC103 combines approved/ cleared surgical staple-line buttress, drug eluting polymers and a chemotherapeutic drug, paclitaxel). ABC103 has been granted US FDA orphan drug designation for this indi...

STENTYS S.A.

Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., (also founder of CoreValve, which was acquired by Medtronic) and Gonzague Issenmann, STENTYS received CE-marking for its flagship products in 2010. Its self-apposing stent adapts to the...

Biocompatibles UK Ltd

Biocompatibles is a leader in advanced biomedical polymers for medical devices and drug delivery. The Company is focused on developing products that will improve patient outcomes in the treatment of cardiovascular disease, cancer and benign tumours. At the heart of Biocompatibles' strength and success are two flexible and versatile polymer technologies and the talented professionals who have devel...

Xtent

XTENT, Inc. develops customizable drug-eluting stent (DES) systems for the treatment of coronary artery disease. XTENT's customizable DES systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Founded in 2001, XTENT was incubated by The Foundry (Redwood City, CA) and incorpora...

PolyActiva

PolyActiva is a pioneering biotechnology company developing drug-polymer conjugates that allow for site specific drug delivery from medical device components such as ocular implants, intra-articular gel implants, and drug-eluting fibers. The Company has developed a novel and scalable manufacturing process that can easily be adapted to existing device compo...

Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a privately held company based in Bedford, MA, focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology. Ocular Therapeutix is focusing on development of drug-eluting punctum plugs for treatment of glaucoma and post-operative inflammation and pain, injectable d...

ITGI Medical LTD

ITGI medical is engaged in research and development, manufacturing and marketing of heterologous tissue covered stents. ITGI's stents are already commercially available in Europe, Israel and Latin America. The world stent market has a value estimation of 6.4 Billion USD, of which 37% are generated in the USA.

OcuMedic, Inc.

OcuMedic, Inc. is the developer of the world’s first, drug-eluting therapeutic lens/clear corneal bandage for the delivery of drugs for the global ophthalmic market. Invented by Mark Byrne, Ph.D. distinguished engineering professor and Head of the Department of Biomedical Engineering at Rowan University, the therapeutics lens is a soft contact develop...

Cardionovum GmbH

“We are well-positioned to be a dominant competitor in the emerging market for drug-eluting balloons (DEBs) as a first-line therapy for many patients, including those with critical limb ischemia (CLI) and those who must undergo repeated interventions, such as diabetics.”

GenSight

GenSight is the world’s leading Enterprise Portfolio management solution. The industry’s only complete platform to enable users to master the complexities of Portfolio Optimization by combining business process consulting, best-of-breed technology and change management. The GenSight approach guides users through the process to ensure they’re ...

The Washington Post

The Washington Post provides award-winning news and understanding about the politics, policies, personalities and institutions that make Washington, D.C. the world's seat of power, and is a critical tool and information source for those who call Washington, D.C. home. In digital form, The Washington Post combines its world-class journalism with the latest ...

Vividion Therapeutics, Inc.

Conventional drug discovery is target-centric; a compound library is screened using a target-specific assay and high-affinity binding ligands are optimized to develop a drug candidate. This approach is limited, as research is performed in artificial systems that fail to account for native protein structure, context and function. Further, conventional targe...

ADMETRx, Inc.

The new mantra in drug discovery sounds simple but it ignores the fact that a compound's "developability" is a sum of the trade-offs of its biopharmaceutical properties. Decisions on lead selection and optimization must balance these complexities. ADMETRx does not assume that the perfect drug candidate is to be found through massive screening efforts. Rather than force an arbitrary "go/no go" deci...

AdverseEvents Inc.

AdverseEvents, Inc. (AEI) is a California-based healthcare informatics company that improves patient safety and reduces systemic healthcare costs through the comprehensive analysis of post-marketing drug side effect data. Utilizing data-mining and analysis technology, through its proprietary RxSuite™ of analytics, AEI makes post-marketing drug safety ...

CBSET

CBSET — Concord Biomedical Sciences & Emerging Technologies — is the preclinical research leader in critically important therapeutic fields such as interventional cardiology, renal disease and dialysis, chronic drug-resistant hypertension, women’s health, minimally invasive surgery, orthopedics, biological and synthetic tissue repair, drug delivery...

Vascular Magnetics, Inc.

Vascular Magnetics is developing novel therapeutic products based on the magnetic targeting of drug-loaded biodegradable particles. The company’s first product in development is a treatment for peripheral artery disease that is designed to target anti-restenotic drugs specifically to diseased arterial sites and deliver doses not achievable with a drug ...

REVA Medical, Inc.

REVA is dedicated to developing minimally invasive medical devices that leverage the Company's proprietary biomaterial and stent technologies to improve the treatment of disease. Guided by a management team and scientific advisors with extensive product development and clinical interventional cardiology experience, REVA's initial focus is the development and eventual commercialization of...

Apredica

Apredica provides contract research services for the evaluation and optimization of the Absorption, Distribution, Metabolism, Elimination, Toxicity - (ADMET) - and Pharmacokinetic properties of drug candidates early in the drug-discovery process.

Ariste Medical, Inc.

Ariste Medical, Inc. is a privately held biotechnology company developing novel, first-in-class, drug-eluting devices to reduce infection, restenosis, and thrombosis. Located in the Memphis Bioworks Foundation incubator within the UT-Baptist Research Park in Memphis, Tenn., the company is leveraging its unique formulation to transform legacy PTFE and ePTFE...

Dalton Chemical Laboratories

Using the over 120 years of accumulated chemistry experience of our Senior Chemists, Dalton has established itself as a major player in the field of Contract Research. From synthetic feasibility analysis to drug discovery, process development and subsequent production, we can play an active role in your drug development program as an objective oriented partner. Custom research services are support...


More From BioPortfolio on "Post-dilatation for Optimization of Drug-eluting Stents (DES) Deployment Assessed by Intravascular Ultrasound Multicenter Analysis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks